ClinicalTrials.gg
TerminatedNCT04852172Updated Sep 19, 2024

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

A Phase 1/2 interventional study of L-citrulline and D5 1/2NS in Acute Vaso Occlusive Crisis (VOC), sponsored by Asklepion Pharmaceuticals, LLC. Terminated at 2 sites in United States. Open to participants aged 6 Years to 21 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Asklepion Pharmaceuticals, LLC · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Impacted by viraemia resulting in higher than expected admissions

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
6 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.

Enrollment
39th of 56
30 · median 63
Started
2021
with 5 others
Phase 1/2
2 of 60
none open now
Registered
40th of 60
by date
Lead sponsor
2 of 60
Asklepion Pharmaceuticals, LLC

Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 39th largest by enrollment of the 56 interventional ones that give a count, is one of 6 that started in 2021, is one of 2 in phase 1/2, and was the 40th registered.

Vaso-Occlusive Crises

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Open to participants now

13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 6 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Vaso-Occlusive Crises with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if intravenous L-citrulline can abrogate an active vaso-occlusive crisis in sickle cell disease, resulting in decreased pain, reduction or elimination of opiate usage, and reduction or elimination of hospital admission. The applicant is developing intravenous L-citrulline (Turnobi™) for treatment of sickle cell disease (SCD). The current development program targets treatment of sickle cell-associated vaso-occlusive crisis (VOC) specifically. The aim of Part 1 is to identify the optimum dose regimens for the Part 2 of the trial which is a double-blind, placebo controlled adaptive 'pick-the-winner' design. This study will allow assignment of more subjects to the better treatment arm/s based on emerging data. The study, initially, will evaluate efficacy and tolerability of incremental doses of intravenous (IV) L-citrulline (Turnobi™) in patients with SCD while receiving standard of care therapy for VOC.

Read the detailed description

Overall Design:

This is a study in children, adolescents, and young adults (6 to 21 years) with SCD presenting to an emergency department (ED) with VOC. Children below age 6 are likely to be recruited in a subsequent phase, once proof of concept is established on optimized dose regimen. Eligible subjects will have documented SCD. Intravenous L citrulline (Turnobi™) or placebo will be administered in addition to standard of care VOC therapy to children, adolescents, and young adults presenting with SCD VOC - defined as painful episode without other apparent causes of pain and without significant organ dysfunction or signs of systemic infection.

This is a single center study, conducted in 2 parts:

Part 1: This is an open-label, ascending dose part of the study. After obtaining the informed consent/assent, the enrolled subjects will be in the ED for up to 7 hours where L-citrulline will be administered as depicted in the dosing panel below. Each dose will be administered sequentially until 5 subjects per dose cohort are accrued.

Dosing panels in Part 1:

25 mg/kg bolus + 9 mg/kg/hr infusion; 50 mg/kg bolus + 9 mg/kg/hr infusion; 100 mg/kg bolus + 9 mg/kg/hr infusion; 100 mg/kg bolus + 11 mg/kg/hr infusion;

After each panel of 5 have been dosed, response to a dose is determined by the Principal Investigator (PI) with the internal review committee based primarily on analgesic effects assessed by review of Visual Analogue Scale (VAS) score, opioid dosing, and tolerability.

If the dose panel is assessed safe and 3 of 5 subjects in a cohort respond to the treatment, the current dose arm will continue to accrue a total of 10 subjects. If the dose panel is assessed as safe; however, fewer than 3 of the 5 subjects respond, the current dose arm will be stopped, and the subjects will be recruited to the next dosing panel.

Two additional panels of 5 to 10 subjects receiving doses outside these ranges may be accrued at the request of the internal review committee if determined necessary to achieve the study's objectives. As long as supported by emerging data, the subjects in these additional panels may receive a lower or higher bolus injection but no greater than 150 mg/kg bolus and/or a lower or higher infusion dose but no greater than 15 mg/kg/hour. Up to 60 subjects may be enrolled in Part 1 of the study with a likely sample size of approximately 40 subjects.

Part 1 of the study is intended to select up to 2 effective and tolerated dose regimens for Part 2 of the study.

Part 2: The optimal dose regimens (at least1 but probably 2) selected from Part 1 will be analyzed in a randomized, double-blind, placebo-controlled adaptive pick-the-winner design. This will allow assignment of more subjects to the better treatment arm/s based on emerging data. Efficacy will be based primarily on analgesic effect assessed by VAS/opioid dose composite, admission or not, and tolerability based on adverse drug reactions by the internal review committee.

A total of 60 subjects will take part in Part 2. Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio. After 30 subjects (10 per treatment arm) have been randomized, an interim analysis will be performed. If the higher dose is providing markedly more pain relief than the lower dose - with no safety issues - then the lower dose will be dropped. Otherwise, if efficacy and safety look similar, the lower dose will be retained, and the higher dose will be dropped. In other words, the most successful active treatment arm will be chosen for further study versus placebo. The internal review committee will be responsible for making this decision. Subsequently, 30 more patients will be randomized in a 1:1 fashion in the remaining 2 study arms (15 patients each). In the unlikely case that the placebo arm demonstrates superior response to both active treatment arms, the interval review committee will recommend discontinuing the study.

If after 30 subjects, it is determined by the internal review committee that 1 of the 2 doses is significantly more effective in subjects with particular characteristics, the less effective L-citrulline dose regimen can be dropped for those subjects, eg, if those with more severe VOC only respond to the higher dose but those with less severe VOC respond equally well to either dose, subjects with severe VOC will be adaptively allocated into a separate stratum and randomized only to the higher dose or placebo.

All subjects in both Part 1 and Part 2 will receive standard of care for analgesia per SCD pain management protocol consistent with the Children's national ED guidance guided individualized care plan irrespective of treatment with study treatment or placebo. The end of the study is defined as the date of the last visit of the last subject in the study or last scheduled procedure the last subject in the study.

03

Conditions studied

  • Acute Vaso Occlusive Crisis (VOC)

Browse trials for

04

Who can participate

Ages eligible
6 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sickle cell disease (all genotypes)
  2. Children, adolescents and young adults between ages 6 to 21 years
  3. In a steady disease state and not in the midst of any acute complication other than VOC due to sickle cell disease at study entry
  4. For female of , a negative urine pregnancy test and using an adequate method of , or denies sexual activity
  5. Subjects or parents or legal guardian of the subject who are willing and able to sign and provide consent and assent (where appropriate for the age of the child).

Exclusion criteria

Exclusion Criteria:

  1. Current pain lasting >3 days
  2. >6 hospital admissions in the prior year
  3. History of opioid dependence/substance abuse
  4. Has been on a clinical trial of a new therapy for sickle cell disease within the last 3 months
  5. Presence of any other complication related to sickle cell disease such as splenic sequestration, hepatic sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, renal dysfunction, dactylitis, acute chest syndrome and other major medical conditions or organ dysfunction
  6. Severe anemia ( \<6 g/dL)
  7. History of red blood cell transfusion within the last 30 days
  8. Systemic therapy within the last 48 hours
  9. Pregnancy or lactation (subjects must have a negative urine pregnancy test)
  10. Serum creatinine levels:

    1. Age 6 to 13 years >0.9 mg/dL
    2. Age 14 to 17 years >1.0 mg/dL
    3. Age >18 years >1.5 mg/dL
  11. Report of fever (>38°C) within last 48 hours
  12. Presence of acute chest syndrome, sepsis, bacterial infection, hemodynamic instability
  13. Subjects with inability to have parental assent given (ages 6 to 17 years) or consent (ages 18 through 21 years).

    Note: Parents or legal guardians can provide consent for subjects who are unable to provide assent (eg, sleepy or preoccupied by their pain).

  14. History of allergic reaction to L-citrulline product
  15. Medications that are known to be with use of L-citrulline
  16. History of diabetes.
  17. Subjects with a baseline International Normalized ratio (INR) >2.0.
  18. Received any blood products within 3 weeks of the screening visit.
  19. Unreliable venous access
  20. The PI considers that the subject will be unable to comply with the study requirements.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Arm 1 (L-citrulline)

    25 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours

    Drug: L-citrulline

  • Active comparator
    Arm 2 (L-citrulline)

    50 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours

    Drug: L-citrulline

  • Active comparator
    Arm 3 (L-citrulline)

    100 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours

    Drug: L-citrulline

  • Active comparator
    Arm 4 (L-citrulline)

    100 mg/kg bolus + 11 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours

    Drug: L-citrulline

  • Active comparator
    Part 2 Arm 1 (L-citrulline)

    Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio. L-citrulline will be administered to the active arm.

    Drug: L-citrulline

  • Placebo comparator
    Part 2 Arm 2 D5 1/2NS

    Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio.

    Other: D5 1/2NS

Interventions

  • L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.

    Also known as: L-CIT, CIT

  • OtherD5 1/2NS

    Saline

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Dose Optimization (Part 1)

    During Part 1 of the study four cohorts will be enrolled. Cohorts will be squentially completed. Each cohort has a different dosing schema.

    Time frame: Collected from enrollment to end of study over 18 months

  2. To determine the how the study medication is processed by the body.

    About 5 milliliters of blood will be collected before study medication is administered and then every 15 minutes to measure how much study drug is in your blood stream. The blood sample collected will be analyzed for Pharmacokinetic parameters Peak of drug in the blood will be measured

    Time frame: Collected from enrollment to Emergency room Discharge, Approximability 7 Hours

  3. To determine the how the study medication is processed by the body.

    About 5 milliliters of blood will be collected before study medication is administered and then every 15 minutes to measure how much study drug is in your blood stream. The blood sample collected will be analyzed for Pharmacokinetic parameters Trough of drug in the blood will be measured

    Time frame: Collected from enrollment to Emergency room Discharge, Approximability 7 Hours

  4. To determine the how the study medication is processed by the body.

    About 5 milliliters of blood will be collected before study medication is administered and then every 15 minutes to measure how much study drug is in your blood stream. The blood sample collected will be analyzed for Pharmacokinetic parameters of steady state concentration (Cmax) of drug in the blood will be measured

    Time frame: Collected from enrollment to Emergency room Discharge, Approximability 7 Hours

  5. To determine the how the study medication is processed by the body.

    About 5 milliliters of blood will be collected before study medication is administered and then every 15 minutes to measure how much study drug is in your blood stream. The blood sample collected will be analyzed for Pharmacokinetic parameters of AUC of drug in the blood will be measured

    Time frame: Collected from enrollment to Emergency room Discharge, Approximability 7 Hours

  6. Change in Visual Analogue Scale (VAS) pain score

    Please note that scale info should be entered in the outcome measure description field: at least 2-point decrease or 30% change in pain intensity VAS or Faces Pain Scale score RANGE from 0 (No pain) to 100 (Maximum Pain) (for subjects 6 to 7 years old) when compared with baseline value; assessed every 15 minutes

    Time frame: Collected from enrollment to end of study over 18 months

  7. Change from baseline in amount of overall opioid use

    Opioid consumption will be recorded from baseline to end of study.

    Time frame: Collected from enrollment to end of study over 18 months

  8. Discharge from ED/hospital within 7 hours

    Time spent in the ED/hospital will be collected

    Time frame: Collected from enrollment to end of study over 18 months

  9. Assessment of safety

    The rate of reported AE analysis and Lab abnormalities for each cohort

    Time frame: Collected from enrollment to end of study over 18 months

Secondary outcomes

  1. Preliminary assessment of pain change measured

    The standard of care Visual Analog Scale (VAS) pain scale will be administered at baseline then every 15 minutes after the start of study

    Time frame: Collected from enrollment to end of study (2-Days)

  2. Preliminary assessment of change of opioid use overall

    The standard of care will be followed for pain management. the amount of opioids consumed will be collected.

    Time frame: Collected from enrollment to end of study (30 Days)

  3. Time to clinical resolution of VOC

    Time to clinical resolution of VOC depicted by sustained VAS score; assessed every 15 minutes

    Time frame: Collected from enrollment to end of study (30 Days)

  4. Duration or length of hospital stay

    Data collected from the ED visit through day 30 follow-up will look at reoccurrence of admission.

    Time frame: Collected from enrollment to end of study (30-Days)

07

Study locations

2 sites
  • Children's National Hospital
    Washington DC, District of Columbia 20010, United States
  • The University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Feb 2024, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
Apr 21, 2021
StartActual
Apr 29, 2021
Primary completionActual
Feb 29, 2024
CompletionActual
Feb 29, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04852172
Lead sponsor
Asklepion Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
Apr 21, 2021
Start date
Apr 29, 2021
Primary completion
Feb 29, 2024
Completion
Feb 29, 2024
Last update
Sep 19, 2024

Study contacts

Gurdyal Kalsi, MD, MFPM
study director · Asklepion Pharmaceuticals, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Citrulline

Start the discussion